Mechanism of osteogenic induction by FK506 via BMP/Smad pathways

Biochemical and Biophysical Research Communications

Volumn 338, Issue 2, 2005, Pages 872-879

  Kugimiya, Fumitaka ^a   Yano, Fumiko ^a   Ohba, Shinsuke ^a   Igawa, Kazuyo ^a   Nakamura, Kozo ^a   Kawaguchi, Hiroshi ^a   Chung, Ung Il ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

BMP; FK506; FKBP12; Osteoblast; Osteogenic differentiation; Smad

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR; FK 506 BINDING PROTEIN; FK 506 BINDING PROTEIN 12; LIGAND; SMAD PROTEIN; SMAD6 PROTEIN; TACROLIMUS; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; ARTICLE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL LINE; DRUG BINDING; HUMAN; HUMAN CELL; MESENCHYME CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

ANIMALS; BONE MORPHOGENETIC PROTEINS; CELL DIFFERENTIATION; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; MESENCHYMAL STEM CELLS; MICE; OSTEOGENESIS; SIGNAL TRANSDUCTION; SMAD PROTEINS; TACROLIMUS;

ADENOVIRIDAE; ANIMALIA;

EID: 27744588940     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2005.10.024     Document Type: Article

References (35)

1. F. Vincenti, S.C. Jensik, R.S. Filo, J. Miller, and J. Pirsch A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years Transplantation 73 2002 775 782
2. J.D. Pirsch, J. Miller, M.H. Deierhoi, F. Vincenti, and R.S. Filo A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group Transplantation 63 1997 977 983
3. A.D. Mayer, J. Dmitrewski, J.P. Squifflet, T. Besse, B. Grabensee, B. Klein, F.W. Eigler, U. Heemann, R. Pichlmayr, M. Behrend, Y. Vanrenterghem, J. Donck, J. van Hooff, M. Christiaans, J.M. Morales, A. Andres, R.W. Johnson, C. Short, B. Buchholz, N. Rehmert, W. Land, S. Schleibner, J.L. Forsythe, D. Talbot, and E. Pohanka Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group Transplantation 64 1997 436 443
4. J. Miller Tacrolimus and mycophenolate mofetil in renal transplant recipients: one year results of a multicenter, randomized dose ranging trial. FK506/MMF Dose-Ranging Kidney Transplant Study Group Transplant Proc. 31 1999 276 277
5. J. Liu, J.D. Farmer Jr., W.S. Lane, J. Friedman, I. Weissman, and S.L. Schreiber Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes Cell 66 1991 807 815
6. S.J. O'Keefe, J. Tamura, R.L. Kincaid, M.J. Tocci, and E.A. O'Neill FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin Nature 357 1992 692 694
7. K.M. Park, J.E. Hay, S.G. Lee, Y.J. Lee, R.H. Wiesner, M.K. Porayko, and R.A. Krom Bone loss after orthotopic liver transplantation: FK 506 versus cyclosporine Transplant Proc. 28 1996 1738 1740
8. H.U. Stempfle, C. Werner, S. Echtler, T. Assum, B. Meiser, C.E. Angermann, K. Theisen, and R. Gartner Rapid trabecular bone loss after cardiac transplantation using FK506 (tacrolimus)-based immunosuppression Transplant Proc. 30 1998 1132 1133
9. T. Koga, Y. Matsui, M. Asagiri, T. Kodama, B. de Crombrugghe, K. Nakashima, and H. Takayanagi NFAT and Osterix cooperatively regulate bone formation Nat. Med. 11 2005 880 885
10. M. Cvetkovic, G.N. Mann, D.F. Romero, X.G. Liang, Y. Ma, W.S. Jee, and S. Epstein The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo Transplantation 57 1994 1231 1237
11. T. Inoue, I. Kawamura, M. Matsuo, M. Aketa, M. Mabuchi, J. Seki, and T. Goto Lesser reduction in bone mineral density by the immunosuppressant, FK506, compared with cyclosporine in rats Transplantation 70 2000 774 779
12. L. Tang, S. Ebara, S. Kawasaki, S. Wakabayashi, T. Nikaido, and K. Takaoka FK506 enhanced osteoblastic differentiation in mesenchymal cells Cell Biol. Int. 26 2002 75 84
13. S. Kaihara, K. Bessho, Y. Okubo, J. Sonobe, K. Kusumoto, Y. Ogawa, and T. Iizuka Effect of FK506 on osteoinduction by recombinant human bone morphogenetic protein-2 Life Sci. 72 2002 247 256
14. S. Kaihara, K. Bessho, Y. Okubo, J. Sonobe, M. Kawai, and T. Iizuka Simple and effective osteoinductive gene therapy by local injection of a bone morphogenetic protein-2-expressing recombinant adenoviral vector and FK506 mixture in rats Gene Ther. 11 2004 439 447
15. M.R. Urist Bone: formation by autoinduction Science 150 1965 893 899
16. J.M. Wozney, V. Rosen, A.J. Celeste, L.M. Mitsock, M.J. Whitters, R.W. Kriz, R.M. Hewick, and E.A. Wang Novel regulators of bone formation: molecular clones and activities Science 242 1988 1528 1534
17. M. Kawabata, and K. Miyazono Bone morphogenetic proteins M.D. Ernesto Canalis Skeletal Growth Factors 2000 Lippincott Williams & Wilkins Philadelphia 269 290
18. J.L. Wrana, and L. Attisano MAD-related proteins in TGF-beta signalling Trends Genet. 12 1996 493 496
19. C. Gruendler, Y. Lin, J. Farley, and T. Wang Proteasomal degradation of Smad1 induced by bone morphogenetic proteins J. Biol. Chem. 276 2001 46533 46543
20. V. Rosen, J. Nove, J.J. Song, R.S. Thies, K. Cox, and J.M. Wozney Responsiveness of clonal limb bud cell lines to bone morphogenetic protein 2 reveals a sequential relationship between cartilage and bone cell phenotypes J. Bone Miner. Res. 9 1994 1759 1768
21. T. Katagiri, A. Yamaguchi, M. Komaki, E. Abe, N. Takahashi, T. Ikeda, V. Rosen, J.M. Wozney, A. Fujisawa-Sehara, and T. Suda Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage J. Cell Biol. 127 1994 1755 1766
22. K. Kusanagi, H. Inoue, Y. Ishidou, H.K. Mishima, M. Kawabata, and K. Miyazono Characterization of a bone morphogenetic protein-responsive Smad-binding element Mol. Biol. Cell 11 2000 555 565
23. A. Hollnagel, V. Oehlmann, J. Heymer, U. Ruther, and A. Nordheim Id genes are direct targets of bone morphogenetic protein induction in embryonic stem cells J. Biol. Chem. 274 1999 19838 19845
24. D.W. Jayme, and K.E. Blackman Culture media for propagation of mammalian cells, viruses, and other biologicals Adv. Biotechnol. Processes 5 1985 1 30
25. M. Huse, Y.G. Chen, J. Massague, and J. Kuriyan Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12 Cell 96 1999 425 436
26. H. Chikuda, F. Kugimiya, K. Hoshi, T. Ikeda, T. Ogasawara, T. Shimoaka, H. Kawano, S. Kamekura, A. Tsuchida, N. Yokoi, K. Nakamura, K. Komeda, U.I. Chung, and H. Kawaguchi Cyclic GMP-dependent protein kinase II is a molecular switch from proliferation to hypertrophic differentiation of chondrocytes Genes Dev. 18 2004 2418 2429
27. R.P. Kershner, and W.E. Fitzsimmons Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation Transplantation 62 1996 920 926
28. J. Fryer, R.W. Yatscoff, E.A. Pascoe, and J. Thliveris The relationship of blood concentrations of rapamycin and cyclosporine to suppression of allograft rejection in a rabbit heterotopic heart transplant model Transplantation 55 1993 340 345
29. C. Movsowitz, S. Epstein, F. Ismail, M. Fallon, and S. Thomas Cyclosporin A in the oophorectomized rat: unexpected severe bone resorption J. Bone Miner. Res. 4 1989 393 398
30. L.C. Hofbauer, C. Shui, B.L. Riggs, C.R. Dunstan, T.C. Spelsberg, T. O'Brien, and S. Khosla Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells Biochem. Biophys. Res. Commun. 280 2001 334 339
31. J. Fukunaga, T. Yamaai, E. Yamachika, Y. Ishiwari, H. Tsujigiwa, K. Sawaki, Y.J. Lee, T. Ueno, S. Kirino, N. Mizukawa, S. Takagi, N. Nagai, and T. Sugahara Expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in rat osteoporosis induced by immunosuppressant FK506 Bone 34 2004 425 431
32. S.S. Varanasi, and H.K. Datta Characterisation of cytosolic FK506 binding protein 12 and its role in modulating expression of Cbfa1 and osterix in ROS 17/2.8 cells Bone 36 2005 243 253
33. S. Govender, C. Csimma, H.K. Genant, A. Valentin-Opran, Y. Amit, R. Arbel, H. Aro, D. Atar, M. Bishay, M.G. Borner, P. Chiron, P. Choong, J. Cinats, B. Courtenay, R. Feibel, B. Geulette, C. Gravel, N. Haas, M. Raschke, E. Hammacher, D. van der Velde, P. Hardy, M. Holt, C. Josten, R.L. Ketterl, B. Lindeque, G. Lob, H. Mathevon, G. McCoy, D. Marsh, R. Miller, E. Munting, S. Oevre, L. Nordsletten, A. Patel, A. Pohl, W. Rennie, P. Reynders, P.M. Rommens, J. Rondia, W.C. Rossouw, P.J. Daneel, S. Ruff, A. Ruter, S. Santavirta, T.A. Schildhauer, C. Gekle, R. Schnettler, D. Segal, H. Seiler, R.B. Snowdowne, J. Stapert, G. Taglang, R. Verdonk, L. Vogels, A. Weckbach, A. Wentzensen, and T. Wisniewski Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients J. Bone Joint Surg. Am. 84-A 2002 2123 2134
34. S.D. Boden, J. Kang, H. Sandhu, and J.G. Heller Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies Spine 27 2002 2662 2673
35. J.K. Burkus, E.E. Transfeldt, S.H. Kitchel, R.G. Watkins, and R.A. Balderston Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2 Spine 27 2002 2396 2408